Format

Send to

Choose Destination
Arch Facial Plast Surg. 2011 Jul-Aug;13(4):247-51. doi: 10.1001/archfacial.2011.3. Epub 2011 Feb 21.

Safety, efficacy, and utility of platelet-rich fibrin matrix in facial plastic surgery.

Author information

1
Division of Facial Plastic and Reconstructive Surgery, The New York Eye and Ear Infirmary, 310 E 14th Street, New York, NY 10003, USA. asclafani@nyee.edu

Abstract

OBJECTIVE:

To evaluate the clinical safety and efficacy of the use of autologous platelet-rich fibrin matrix (PRFM) in facial plastic surgery.

METHODS:

Medical charts of the last 50 patients with at least 3 months of follow-up who were treated by the author with PRFM for aesthetic purposes were reviewed for patient satisfaction, objective clinical results, and adverse events.

RESULTS:

The study cohort of patients was followed up for a mean (SD) of 9.9 (8.0) months (range, 3-30 months). Most patients were treated for deep nasolabial folds, while the volume-depleted midface region, superficial rhytids, and acne scars were other commonly treated areas. The patients underwent an average of 1.6 treatments (range, 1-5 treatments). No patients reported any swelling lasting longer than 5 days, and most noted only minimal bruising lasting for 1 to 3 days. Most patients were satisfied with the results of their treatments, although 1 patient felt that there was limited or no improvement after 2 treatments.

CONCLUSIONS:

Autologous PRFM treatment is a well-tolerated, excellent choice for use in the face. Further studies on the precise mechanism of action of PRFM are ongoing.

PMID:
21339469
DOI:
10.1001/archfacial.2011.3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center